ER-KANG(300267) Quan Jing Wang·2025-05-13 01:29Group 1 - The 2024 annual performance briefing of Erkang Pharmaceutical (300267) will be held on May 12, 2025, focusing on the optimization and upgrade of the entire drug production quality management chain through the inclusion of production quality management standards for pharmaceutical excipients [1] - The new regulations require pharmaceutical excipient manufacturers to enhance their quality management systems, ensure compliance with drug requirements, and strengthen risk management and production processes [1] - The revised "Drug Production Quality Management Standards (2010 Revision)" will promote the market capacity and competitiveness of compliant pharmaceutical excipient companies [1] Group 2 - Erkang Pharmaceutical is a leading domestic enterprise in pharmaceutical excipients, having developed into a multinational group that integrates pharmaceutical intermediates, raw materials, excipients, chemical drugs, and traditional Chinese medicine [2] - The company has established partnerships with over 3,000 pharmaceutical enterprises and currently offers 127 types of pharmaceutical excipients, 73 types of raw materials, and holds 282 approved drug numbers along with 195 domestic and international authorized patents [2]